Immunosuppression and Cancer Risk

• A weakened immune system substantially raises a person’s risk of developing certain cancers, largely because it can no longer reliably detect and clear abnormal cells.
• This elevated risk comes from two different sources that should not be blended: medications that intentionally suppress immunity, such as those used after organ transplantation or for autoimmune disease, and underlying conditions such as HIV infection that weaken the immune system directly.
• Chronic inflammation and the reactivation of viruses such as Epstein-Barr virus, HPV, and HHV-8 — normally controlled by a healthy immune system — are key mechanisms linking immunosuppression to cancer.
• Regular cancer screening, vigilant symptom monitoring, and any adjustment of immunosuppressive medication — always directed by the treating care team — help manage this risk without compromising the transplant or the underlying condition.
• Understanding this link supports proactive health management and earlier detection of cancer in people who are immunosuppressed.

Understanding Immunosuppression and Cancer Risk

What is Immunosuppression?

Immunosuppression refers to a reduced ability of the immune system to mount a normal defensive response. This state can be intentionally induced — for example, through the medications given to organ transplant recipients to prevent organ rejection, or through immune-modulating drugs used to control autoimmune disease — or it can result from an underlying condition such as HIV infection, an inherited immunodeficiency, or the gradual decline in immune function that comes with advanced age. In every case, the immune system normally serves as a defense not only against infections but also against abnormal cells that could become cancerous; when that defense is weakened, the body’s capacity to identify and eliminate these cells is diminished, leaving a window in which cancer can develop unchecked.

Overview of Increased Cancer Incidence

Numerous studies confirm that people with a weakened immune system face a higher incidence of certain cancers than the general population — though how much higher, and which cancers, depends heavily on the cause of the immunosuppression. Solid organ transplant recipients take immunosuppressive medication indefinitely to keep a transplanted organ from being rejected, and this group has been tracked closely for cancer risk: the National Cancer Institute’s Transplant Cancer Match Study, which links national transplant-registry and cancer-registry records, puts their overall cancer risk at roughly double to quadruple that of people who have not had a transplant, with much of the excess coming from cancers tied to viral infection. That figure describes solid organ recipients specifically; it does not automatically extend to people who have had a bone marrow or stem cell transplant, whose immune reconstitution follows a different course. A separate and distinct population — people living with HIV — also faces elevated cancer risk, but for different reasons and to a different degree by cancer type, discussed further below.

Mechanisms: How Immunosuppression Fuels Cancer

Impaired Immune Surveillance

A central way that immunosuppression contributes to cancer is by undermining immune surveillance — the immune system’s ongoing patrol for abnormal cells throughout the body. Specialized cells, including natural killer (NK) cells and cytotoxic T lymphocytes, are normally responsible for recognizing and destroying cells that have begun to transform before they can multiply into a tumor. When immunosuppression reduces the number or activity of these cells, transformed cells are more likely to evade detection and continue dividing. This failure of surveillance does not by itself cause cancer to form, but it removes one of the body’s main checks on cancers that would otherwise be caught and cleared early.

Chronic Inflammation and Viral Reactivation

Beyond surveillance, immunosuppression can promote cancer through chronic inflammation and the reactivation of latent viruses. Ongoing inflammation creates a tissue environment that favors cell proliferation, blunts apoptosis (programmed cell death), and increases DNA damage — conditions that make cancerous transformation more likely over time. Many people also carry oncogenic viruses that a healthy immune system normally keeps in check, including Epstein-Barr virus (EBV), human papillomavirus (HPV), and human herpesvirus 8 (HHV-8, also known as Kaposi sarcoma-associated herpesvirus). When immune control weakens, these viruses can reactivate or persist and drive specific cancers: EBV reactivation, for instance, is strongly associated with post-transplant lymphoproliferative disorder (PTLD), a lymphoma that can develop in transplant recipients, while HHV-8 is linked to Kaposi sarcoma and HPV to cervical, anal, and oropharyngeal cancer, among others.

Common Causes of Immunosuppression & Associated Cancers

Immunosuppressive Medications

Immunosuppressive medications are prescribed in two quite different clinical contexts, and the cancer-risk evidence for each is not interchangeable. The first is organ transplantation, where lifelong immunosuppression is required to prevent rejection; this is the population captured in the two-to-four-times risk figure described above. Transplant recipients commonly take calcineurin inhibitors (such as cyclosporine and tacrolimus), antimetabolites (such as azathioprine and mycophenolate mofetil), and corticosteroids, and that same research links this regimen to an elevated incidence of non-Hodgkin lymphoma, Kaposi sarcoma, HPV-related cancers (including cervical, anal, and oral cancers), liver cancer linked to hepatitis B or C, cancers of the kidney, thyroid, and lung, and skin cancers such as squamous cell and basal cell carcinoma. The second context is autoimmune disease — conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease — where similar or related drugs, including some of the newer biologic agents, are prescribed to control inflammation rather than to prevent organ rejection. Cancer-risk research in this group is drug-specific and generally shows smaller and more variable effects than in transplantation, so the transplant-population risk figures above should not be assumed to apply directly to someone taking an immunosuppressive medication for an autoimmune condition.

Underlying Conditions and Transplant Status

Beyond medication, certain underlying conditions cause immunosuppression directly. HIV infection is the clearest example: the virus attacks the immune system itself, and the resulting immunosuppression raises the risk of a specific group of cancers, most of them linked to the viruses named above. A 2025 JAMA Oncology analysis of HIV-related cancer trends in the United States found that, from 2015 through 2019, several virus-related cancers were diagnosed far more often in people with HIV than in people without it: Kaposi sarcoma over 200-fold, anal cancer close to 20-fold, and cervical cancer three- to four-fold, among other elevations. These three cancers — cervical cancer, aggressive non-Hodgkin lymphoma, and Kaposi sarcoma — used to be labeled “AIDS-defining cancers” as a group, but that label is falling out of favor, partly because cervical cancer, unlike the other two, turns out to be only loosely connected to how severely a person’s immune system is suppressed. After combination antiretroviral therapy came into widespread use starting around 1996, Kaposi sarcoma and non-Hodgkin lymphoma rates among people with HIV fell substantially, though both cancers are still diagnosed more often in this group than in those without HIV. A related but distinct group includes people with inherited immunodeficiency syndromes and those who have undergone hematopoietic stem cell (bone marrow) transplantation; both face increased cancer vulnerability from chronic immune dysregulation, though — as noted above — this is a different population from solid organ transplant recipients, and the risk figures for one group should not be applied to the other.

Strategies for Managing Cancer Risk

Regular Screening and Monitoring

Because the pattern of risk differs by cause, screening is tailored to the specific reason a person is immunosuppressed rather than applied as a single blanket rule; a transplant team, oncologist, or HIV specialist typically sets the actual schedule. Some elements of that individualized screening are well defined:

• Dermatological Exams: Full-body skin checks by a dermatologist, since squamous cell carcinoma, basal cell carcinoma, and melanoma occur at increased frequency in transplant recipients, as described above; how often exams are needed is set by the transplant team.
• Cervical Cancer Screening: Women living with HIV are advised to begin Pap testing as soon as HIV is diagnosed and continue for life, adding HPV co-testing from age 30.
• HPV Vaccination: Because HPV, EBV, and HHV-8 infection sit behind several of the cancers described above, the Centers for Disease Control and Prevention recommends a three-dose HPV vaccine series — rather than the two doses used in most adolescents — for immunocompromised people, including those with HIV, aged 9 through 26.
• Colorectal Cancer Screening: Scheduled and adjusted for individual risk by the treating team, following the same general framework used in the wider population.
• Lymphoma Surveillance: Prompt evaluation of unexplained fever, night sweats, or swollen lymph nodes, which can be early signs of lymphoma in this population.

Optimizing Immunosuppressive Regimens

Because immunosuppression itself is medically necessary — to prevent organ rejection or to control a serious autoimmune disease — cancer prevention cannot simply mean stopping or reducing these drugs on a patient’s own initiative. Physicians instead work to use the lowest effective dose, and where more than one option is clinically appropriate, they may weigh the relative cancer risk of the available agents. If cancer does develop, the treating team may modify or temporarily reduce the immunosuppressive regimen, but only as part of a carefully supervised plan that weighs the risk of organ rejection or disease flare against the benefit to cancer treatment. This balancing act is highly individual, and decisions about it belong to the patient’s transplant physician, rheumatologist, gastroenterologist, or oncologist working together — never to unsupervised changes in medication.

Frequently Asked Questions

What types of cancers are most common in immunosuppressed individuals?

The specific cancers vary by the cause of immunosuppression, but many are linked to the same group of viruses described above. In solid organ transplant recipients, non-Hodgkin lymphoma, skin cancers (particularly squamous cell carcinoma), and Kaposi sarcoma are among the most consistently elevated, alongside HPV- and hepatitis-related cancers. In people living with HIV, cervical cancer, aggressive subtypes of non-Hodgkin lymphoma, and Kaposi sarcoma carry some of the largest relative increases. Because these figures come from different populations studied in different ways, they describe separate pictures of risk rather than a single number for “immunosuppressed patients” as a whole.

Can immunosuppressive drugs be stopped to reduce cancer risk?

No one should stop or change an immunosuppressive medication on their own to try to lower cancer risk. Doing so can trigger organ rejection in a transplant recipient or a serious flare in someone with an autoimmune disease, either of which can be life-threatening. If cancer risk, or an actual cancer diagnosis, raises the question of adjusting immunosuppression, that decision is made by the treating physician — the transplant team, rheumatologist, or gastroenterologist, depending on the reason for treatment — who weighs the risk of rejection or flare against the potential benefit. Any change is planned and monitored by that team, not made unilaterally by the patient.

How often should immunosuppressed patients be screened for cancer?

There is no single interval that applies to everyone; the right frequency depends on why a person is immunosuppressed, their age, sex, and other individual risk factors, and it is set by their treating clinician rather than a fixed calendar. What is consistent across groups is that screening tends to be more frequent, or to start earlier, than in the general population — cervical cancer screening for women with HIV, for instance, begins at the time of HIV diagnosis rather than waiting for the usual starting age. Patients should ask their transplant team, HIV specialist, or rheumatologist what specific screening schedule applies to their own situation, since that schedule is individualized rather than standardized.

Sources

• National Cancer Institute – Immunosuppression
• National Cancer Institute – Transplant Cancer Match Study – Background and Purpose
• National Cancer Institute – HIV Infection and Cancer Risk
• Centers for Disease Control and Prevention – HPV Vaccine Recommendations for Health Care Providers